CLRB Cellectar Biosciences, Inc.
$2.31▼ -1.70%
Healthcare
Other
After hours
$2.31▲ +0.00%
Sep 11, 7:50 PM ET
Volume 38.2K
Avg Volume (10D) 33.3K
Key Metrics & Fundamentals
Market Cap
$21.83M
P/E Ratio
–
Div Yield
–%
52W Range
2.20 - 6.52
% vs 50 MA
-7.38%
% vs 200 MA
-19.06%
RSI-14
37.4
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.60
Free Cash Flow
-$6.01M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$7.29M
COGS
–
Operating Exp
$7.20M
Operating Income
-$7.20M
EBIT
-$7.20M
Pretax Income
-$6.93M
Net Income
-$6.93M
EPS (Diluted)
-0.57
Price & Volume History
Loading chart…
Recent News
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 20, 2026 2:13 PM
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
GuruFocus.com · Aug 17, 2026 9:02 PM
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 1:03 AM
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire · Aug 13, 2026 11:15 AM
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
GlobeNewswire · Jul 30, 2026 12:05 PM
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
GlobeNewswire · Jul 15, 2026 11:30 AM
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk
Simply Wall St. · Jul 11, 2026 11:10 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CLRB's money flow as a full page
Social Sentiment
Avg +0.10 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.